ARDS Aridis Pharmaceuticals has 2 Phase 3 Clinical Trials for 2022, one Phase 2a study, a fully human monoclonal antibody (mAb) cocktail against COVID and a funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.
And the Market Cap is only 23.892Mil.
In my opinion this stock can double in trice anytime, their pipeline is highly undervalued.